Vitrolife (Sweden) Performance
| VITR Stock | SEK 169.40 0.90 0.53% |
The entity has a beta of 0.34, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Vitrolife's returns are expected to increase less than the market. However, during the bear market, the loss of holding Vitrolife is expected to be smaller as well. At this point, Vitrolife AB has a negative expected return of -0.38%. Please make sure to validate Vitrolife's potential upside, kurtosis, daily balance of power, as well as the relationship between the skewness and accumulation distribution , to decide if Vitrolife AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Vitrolife AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 973.6 M | |
| Total Cashflows From Investing Activities | -6.5 B |
Vitrolife |
Vitrolife Relative Risk vs. Return Landscape
If you would invest 21,560 in Vitrolife AB on December 21, 2024 and sell it today you would lose (4,620) from holding Vitrolife AB or give up 21.43% of portfolio value over 90 days. Vitrolife AB is generating negative expected returns and assumes 2.6086% volatility on return distribution over the 90 days horizon. Simply put, 23% of stocks are less volatile than Vitrolife, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Vitrolife Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vitrolife's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vitrolife AB, and traders can use it to determine the average amount a Vitrolife's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1463
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VITR |
Estimated Market Risk
| 2.61 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.38 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vitrolife is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vitrolife by adding Vitrolife to a well-diversified portfolio.
Vitrolife Fundamentals Growth
Vitrolife Stock prices reflect investors' perceptions of the future prospects and financial health of Vitrolife, and Vitrolife fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vitrolife Stock performance.
| Return On Equity | 0.0246 | |||
| Return On Asset | 0.0205 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 28.19 B | |||
| Shares Outstanding | 135.45 M | |||
| Price To Earning | 58.44 X | |||
| Price To Book | 1.61 X | |||
| Price To Sales | 8.73 X | |||
| Revenue | 1.68 B | |||
| EBITDA | 576.66 M | |||
| Cash And Equivalents | 630.09 M | |||
| Cash Per Share | 4.11 X | |||
| Total Debt | 2.03 B | |||
| Debt To Equity | 4.90 % | |||
| Book Value Per Share | 123.61 X | |||
| Cash Flow From Operations | 384.31 M | |||
| Earnings Per Share | 2.57 X | |||
| Total Asset | 19.43 B | |||
| Retained Earnings | 390 M | |||
| Current Asset | 467 M | |||
| Current Liabilities | 140 M | |||
About Vitrolife Performance
Assessing Vitrolife's fundamental ratios provides investors with valuable insights into Vitrolife's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vitrolife is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Vitrolife AB , a medical device company, develops, produces, and markets products for assisted reproduction. Vitrolife AB was founded in 1981 and is headquartered in Gothenburg, Sweden. Vitrolife operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 415 people.Things to note about Vitrolife AB performance evaluation
Checking the ongoing alerts about Vitrolife for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vitrolife AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vitrolife AB generated a negative expected return over the last 90 days | |
| About 32.0% of the company outstanding shares are owned by insiders |
- Analyzing Vitrolife's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vitrolife's stock is overvalued or undervalued compared to its peers.
- Examining Vitrolife's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vitrolife's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vitrolife's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vitrolife's stock. These opinions can provide insight into Vitrolife's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vitrolife Stock Analysis
When running Vitrolife's price analysis, check to measure Vitrolife's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vitrolife is operating at the current time. Most of Vitrolife's value examination focuses on studying past and present price action to predict the probability of Vitrolife's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vitrolife's price. Additionally, you may evaluate how the addition of Vitrolife to your portfolios can decrease your overall portfolio volatility.